

Note: This document has been translated from the Japanese-language original (hereinafter, the "original") for reference purposes only. In the event of any discrepancy between this translated document and the original, the original shall prevail. The original of Quarterly Consolidated Financial Statements has undergone a review by the Company's audit firm. Please refer to the Japanese review report for details.



February 3, 2026

Summary of Consolidated Financial Results for Third Quarter Fiscal Year 2025 (Under IFRS)

Company name: Sumitomo Chemical Co., Ltd.
 Listing: Tokyo Stock Exchange
 Securities code: 4005
 URL: <https://www.sumitomo-chem.co.jp/english/>
 Representative: Nobuaki Mito, Representative Director & President
 Inquiries: Shunji Kobayashi, General Manager, Corporate Communications Dept.
 Telephone: +81-3-5201-0200
 Scheduled date to commence dividend payments: —
 Preparation of supplementary material on financial results: Yes
 Holding of financial results briefing: Yes (for institutional investors and analysts)

(All amounts are rounded to the nearest million yen.)

1. Consolidated Financial Results for Third Quarter Fiscal Year 2025 (April 1, 2025 to December 31, 2025)

(1) Consolidated Operating Results

(Percentages indicate year-on-year changes.)

	Sales revenue		Core operating income		Operating income		Net income		Net income attributable to owners of the parent		Total comprehensive income	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Q3 FY2025	1,706,327	(10.4)	186,834	211.1	180,416	24.1	144,146	254.2	87,363	205.7	215,977	—
Q3 FY2024	1,904,833	5.4	60,065	—	145,434	—	40,694	—	28,581	—	977	—

	Basic earnings per share	Diluted earnings per share
	Yen	Yen
Q3 FY2025	53.38	53.36
Q3 FY2024	17.47	17.47

Reference: Share of profit or loss of investments accounted for using the equity method

Q3 FY2025: ¥ (43,212)million Q3 FY2024: ¥ 32,644 million

Income before taxes

Q3 FY2025: ¥ 144,399 million Q3 FY2024: ¥ 40,071 million

*Core operating income is a gain and loss concept that reflects recurring earning capacity by deducting gains and losses incurred by non-recurring factors from operating income, which includes the share of profits or losses from investments accounted for using the equity method.

(2) Consolidated Financial Position

	Total assets	Total equity	Equity attributable to owners of the parent	Ratio of equity attributable to owners of the parent to total assets
As of	Millions of yen	Millions of yen	Millions of yen	%
December 31, 2025	3,510,426	1,266,153	1,029,918	29.3
March 31, 2025	3,439,784	1,074,415	900,790	26.2

2. Dividends

	Dividends per share				
	1st quarter end	2nd quarter end	3rd quarter end	Year-end	Annual
	Yen	Yen	Yen	Yen	Yen
FY2024	—	3.00	—	6.00	9.00
FY2025	—	6.00	—		
FY2025 (Forecast)				7.50	13.50

Note: Revision of dividend forecasts from the latest announcement: Yes

3. Consolidated Financial Forecasts for Fiscal Year 2025 (April 1, 2025 to March 31, 2026)

(Percentages indicate year-on-year changes.)

	Sales revenue		Core operating income		Operating income		Net income attributable to owners of the parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full-year of FY2025	2,300,000	(11.8)	200,000	42.3	165,000	(14.5)	55,000	42.5	33.61

Note: Revision of financial forecasts from the latest announcement: Yes

Notes:

(1) Significant changes in the scope of consolidation during the period: Yes

Newly included: —

Excluded: 1 company (XUYOU Electronic Materials (Wuxi) Co., Ltd.)

(2) Changes in accounting policies and changes in accounting estimates

(i) Changes in accounting policies required by IFRS: None

(ii) Changes in accounting policies due to other reasons: None

(iii) Changes in accounting estimates: None

(3) Number of shares issued (common shares)

(i) Total number of shares issued at the end of the period (including treasury shares)

As of December 31, 2025	1,657,914,399 shares
As of March 31, 2025	1,657,217,608 shares

(ii) Number of treasury shares at the end of the period

As of December 31, 2025	20,524,806 shares
As of March 31, 2025	20,517,033 shares

(iii) Average number of shares outstanding during the period

Nine Months ended December 31, 2025	1,636,629,008 shares
Nine Months ended December 31, 2024	1,635,875,454 shares

*Review of the Japanese-language original of the attached quarterly consolidated financial statements by certified public accountants or an audit firm: Yes (voluntary)

*Notes to appropriate use of forecasts and other special items:

Descriptions regarding forward-looking statements about the future performance of the Company contained in this summary are based on information currently available to the Company and certain assumptions judged reasonable and involve risks and uncertainties. The important factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, general economic conditions in the Company's markets; demand for, and competitive pricing pressure on, the Company's products in the marketplace; rise in prices of raw materials; and fluctuations in foreign exchange rates.

*This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

Attachments

1. Summary of Operating Results for Third Quarter Fiscal Year 2025	2
(1) Operating Results	2
(2) Consolidated Financial Position	3
(3) Consolidated Forecast and Other Forward-Looking Information	3
2. Consolidated Financial Statements and Major Notes	5
(1) Consolidated Statement of Financial Position	5
(2) Consolidated Statement of Income and Consolidated Statement of Comprehensive Income	7
(3) Consolidated Statement of Changes in Equity	9
(4) Consolidated Statement of Cash Flows	11
(5) Notes to Consolidated Financial Statements	12
(Framework of Financial Report)	12
(Going Concern Assumption)	12
(Segment Information)	12

1. Summary of Operating Results for Third Quarter Fiscal Year 2025

(1) Operating Results

For Q3 FY2025, the Group's sales revenue decreased by ¥198.5 billion compared to Q3 FY2024, to ¥1,706.3 billion. In terms of profits and losses, core operating income* was ¥186.8 billion, operating income was ¥180.4 billion, and net income attributable to owners of the parent was ¥87.4 billion. Results in every category of income were higher than in Q3 FY2024.

*Core operating income is a gain and loss concept that reflects recurring earning capacity by deducting gains and losses incurred by non-recurring factors from operating income, which includes the share of profits or losses from investments accounted for using the equity method.

The financial results by reportable segment for Q3 FY2025 are as follows:

Agro & Life Solutions

Shipments of crop protection chemicals were strong, particularly in Japan and India. However, methionine (feed additive) faced deteriorating market conditions and a decline in shipments compared to Q3 FY2024. In addition, the stronger yen had a negative effect on sales from subsidiaries outside of Japan when converted into yen. As a result, sales revenue decreased by ¥16.2 billion compared to Q3 FY2024, to ¥346.9 billion. Despite the decrease in sales revenue, core operating income increased by ¥8.6 billion compared to Q3 FY2024, to ¥28.1 billion, due to factors such as the shipments of crop protection chemicals mentioned above.

ICT & Mobility Solutions

In addition to the impact of fundamental structural reforms implemented for the polarizing film business for large-size liquid crystal displays, there was also a decrease in the sales prices of display-related materials due to severe price competition. Market conditions for semiconductor processing materials continue to slowly recover, and shipments have increased, but the business also faced increasing fixed costs and raw material prices. In addition, the stronger yen decreased export income and negatively impacted sales from subsidiaries outside of Japan when converted into yen. As a result, sales revenue decreased by ¥29.4 billion compared to Q3 2024, to ¥431.8 billion, and core operating income decreased by ¥13.2 billion compared to Q3 2024, to ¥46.5 billion.

Advanced Medical Solutions

Oligonucleotide production and shipments increased, but sales of affiliated companies decreased. As a result, sales revenue decreased by ¥5.1 billion compared to Q3 2024, to ¥35.6 billion, and core operating income decreased by ¥0.9 billion, to ¥0.3 billion.

Essential & Green Materials

Shipments of the sales subsidiary declined because of the periodic shutdown maintenance at Rabigh Refining and Petrochemical Company (hereinafter, "Petro Rabigh"), an affiliated company accounted for using the equity method. In addition, shipments of aluminum and other products decreased due to the Group's exit from the business in FY2024, while shipments of synthetic resins decreased following the exit from the business in FY2025. As a result, sales revenue decreased by ¥161.9 billion compared to Q3 2024, to ¥511.0 billion. Core operating income increased by ¥64.1 billion compared to Q3 2024, to ¥19.8 billion, due to a gain on the sale of a portion of the Group's shares in Petro Rabigh, as well as improved trade terms for Petro Rabigh and for synthetic resins and other products.

Sumitomo Pharma

Sales revenue decreased in Japan and Asia, but in North America there was an increase in sales of ORGOVYX® (therapeutic agent for advanced prostate cancer) and GEMTESA® (therapeutic agent for overactive bladder). Sales revenue was further increased by the recording of an ORGOVYX® sales milestone. As a result, sales revenue increased by ¥53.6 billion compared to Q3 FY2024, to ¥346.4 billion. Core operating income increased by ¥86.9 billion compared to Q3 FY2024, to ¥111.2 billion. In addition to the benefit of higher sales revenue, there was a reduction in selling, general and administrative expenses, including research and development expenses, resulting from the effects of business structure improvements, and there was also a gain posted on the partial divestiture of the Asian business. Sales revenue and core operating income differ between this segment and the results reported by Sumitomo Pharma, Co., Ltd., a consolidated subsidiary of Sumitomo Chemical Co., Ltd., due to the Group's contract and manufacturing business for regenerative medicine and cell therapy products not being included in this segment and because of the Group's consolidated account reporting.

Others

In addition to the above five segments, the Group supplies electric power and steam, and also provides transportation and warehousing. Sales revenue decreased by ¥39.4 billion compared to Q3 2024, to ¥34.6 billion, due to the sale of the radiopharmaceutical business and other businesses in FY2024. Core operating income decreased by ¥18.8 billion, to ¥5.0 billion, also because Sumitomo Bakelite Co., Ltd. is no longer accounted for using the equity method, following a partial transfer of shares in FY2024.

(2) Consolidated Financial Position

As of the end of Q3 FY2025, total assets increased by ¥70.6 billion compared to the end of FY2024, to ¥3,510.4 billion, mainly due to an increase in inventories.

Total liabilities decreased by ¥121.1 billion compared to the end of FY2024, to ¥2,244.3 billion. Interest-bearing liabilities decreased by ¥64.6 billion compared to the end of FY2024, to ¥1,221.5 billion.

Total equity (including non-controlling interests) increased by ¥191.7 billion compared to the end of FY2024, to ¥1,266.2 billion, because of increases in other components of equity and non-controlling interests. The ratio of equity attributable to the owners of the parent increased by 3.2 percentage points compared to the end of FY2024, to 29.3%.

(3) Consolidated Forecast and Other Forward-Looking Information

Based on recent performance trends, the Company has made revisions to its consolidated financial forecast for the full year ending March 31, 2026, previously announced on November 4, 2025, as detailed below.

Revisions to Consolidated Financial Forecast for the Full Year Ending March 31, 2026 (April 1, 2025 – March 31, 2026)

	Sales Revenue	Core Operating Income	Operating Income	Net Income Attributable to Owners of the Parent	Earnings per Share (yen)
Previous forecast (A)	2,290,000	185,000	160,000	45,000	27.50
Revised forecast (B)	2,300,000	200,000	165,000	55,000	33.61
Variance in amount (B-A)	10,000	15,000	5,000	10,000	
Variance in percentage (%)	0.4%	8.1%	3.1%	22.2%	
Results for the full year ended March 31, 2025	2,606,281	140,519	193,033	38,591	23.59

Reasons for the Revision

Regarding the consolidated financial results for FY2025, shipments of semiconductor processing materials in the ICT & Mobility Solutions segment are forecasted to increase. The Company took into account uncertainty in the business environment and incorporated risks into its previous financial forecast, but the Company has made steady progress in its business activities. Due to this, the Company expects that sales revenue and core operating income will exceed its previous forecast.

Operating income and net income attributable to owners of the parent are also expected to exceed the previous forecast due to the increase in core operating income.

Because of the upward revisions as stated above, the Company decided to revise the projected year-end dividend to ¥7.5 per share. As a result, the Company's annual dividend will be ¥13.5 per share.

The revised forecast is based on information currently available, and actual performance may vary due to various factors in the future.

(Supplemental information)

Consolidated Financial Forecast by Segment for the Full Year Ending March 31, 2026

(Millions of yen)

		FY2025 Previous Forecast (A)	FY2025 Revised Forecast (B)	Variance in Amount (B-A)
Agro & Life Solutions	Sales revenue	530,000	530,000	-
	Core operating income	55,000	55,000	-
ICT & Mobility Solutions	Sales revenue	550,000	560,000	10,000
	Core operating income	53,000	55,000	2,000
Advanced Medical Solutions	Sales revenue	60,000	60,000	-
	Core operating income	4,000	4,000	-
Essential & Green Materials	Sales revenue	680,000	680,000	-
	Core operating income	13,000	13,000	-
Sumitomo Pharma	Sales revenue	420,000	420,000	-
	Core operating income	100,000	100,000	-
Others & Adjustments	Sales revenue	50,000	50,000	-
	Core operating income	(40,000)	(27,000)	13,000
Total	Sales revenue	2,290,000	2,300,000	10,000
	Core operating income	185,000	200,000	15,000

2. Consolidated Financial Statements and Major Notes
(1) Consolidated Statement of Financial Position

Millions of yen	As of December 31, 2025	As of March 31, 2025
Assets		
Current assets:		
Cash and cash equivalents	¥ 214,768	¥ 209,838
Trade and other receivables	604,637	593,836
Other financial assets	62,115	45,015
Inventories	661,400	625,243
Other current assets	57,872	49,993
Subtotal	1,600,792	1,523,925
Assets held for sale	—	59,209
Total current assets	1,600,792	1,583,134
Non-current assets:		
Property, plant and equipment	773,384	759,266
Goodwill	270,092	257,811
Intangible assets	228,279	239,319
Investments accounted for using the equity method	200,345	287,977
Other financial assets	296,252	177,405
Retirement benefit assets	74,517	72,618
Deferred tax assets	37,931	34,608
Other non-current assets	28,834	27,646
Total non-current assets	1,909,634	1,856,650
Total assets	¥ 3,510,426	¥ 3,439,784

Liabilities and equity**Liabilities**

Current liabilities:

Bonds and borrowings	¥	256,022	¥	252,892
Trade and other payables		473,589		488,132
Other financial liabilities		60,535		81,364
Income taxes payable		8,785		10,627
Provisions		102,724		89,711
Other current liabilities		118,247		109,360
Subtotal		1,019,902		1,032,086
Liabilities directly associated with assets held for sale		—		6,661
Total current liabilities		1,019,902		1,038,747

Non-current liabilities:

Bonds and borrowings		965,463		1,033,236
Other financial liabilities		88,566		91,157
Retirement benefit liabilities		23,781		24,841
Provisions		26,033		25,974
Deferred tax liabilities		93,170		111,048
Other non-current liabilities		27,358		40,366
Total non-current liabilities		1,224,371		1,326,622
Total liabilities		2,244,273		2,365,369

Equity

Share capital		90,179		90,059
Capital surplus		117		—
Retained earnings		697,783		640,611
Treasury shares		(8,364)		(8,361)
Other components of equity		250,203		174,871
Other comprehensive income associated with assets held for sale		—		3,610
Equity attributable to owners of the parent		1,029,918		900,790
Non-controlling interests		236,235		173,625
Total equity		1,266,153		1,074,415
Total liabilities and equity	¥	3,510,426	¥	3,439,784

(2) Consolidated Statement of Income and Consolidated Statement of Comprehensive Income

Consolidated Statement of Income

Third Quarter ended December 31, 2025 and 2024

Millions of yen	Q3 FY2025		Q3 FY2024	
Sales revenue	¥	1,706,327	¥	1,904,833
Cost of sales		(1,177,623)		(1,367,051)
Gross profit		528,704		537,782
Selling, general and administrative expenses		(416,684)		(446,357)
Other operating income		124,218		45,701
Other operating expenses		(12,610)		(24,336)
Share of profit (loss) of investments accounted for using the equity method		(43,212)		32,644
Operating income		180,416		145,434
Finance income		12,395		34,757
Finance expenses		(48,412)		(140,120)
Income before taxes		144,399		40,071
Income tax expenses		(253)		623
Net income		144,146		40,694
Net income attributable to:				
Owners of the parent		87,363		28,581
Non-controlling interests		56,783		12,113
Net income	¥	144,146	¥	40,694

Yen	Q3 FY2025		Q3 FY2024	
Earnings per share:				
Basic earnings per share		53.38		17.47
Diluted earnings per share		53.36		17.47

Consolidated Statement of Comprehensive Income

Third Quarter ended December 31, 2025 and 2024

Millions of yen	Q3 FY2025		Q3 FY2024	
Net income	¥	144,146	¥	40,694
Other comprehensive income:				
Items that will not be reclassified to profit or loss				
Remeasurements of financial assets (equity instruments) measured at fair value through other comprehensive income		27,108		(22,306)
Remeasurements of defined benefit plans		338		(136)
Share of other comprehensive income of investments accounted for using the equity method		2,481		1,942
Total items that will not be reclassified to profit or loss		29,927		(20,500)
Items that may be subsequently reclassified to profit or loss				
Remeasurements of financial assets (debt instruments) measured at fair value through other comprehensive income		58		(52)
Cash flow hedge		(12)		(254)
Exchange differences on conversion of foreign operations		55,080		(12,511)
Share of other comprehensive income of investments accounted for using the equity method		(13,222)		(6,400)
Total items that may be subsequently reclassified to profit or loss		41,904		(19,217)
Other comprehensive income, net of taxes		71,831		(39,717)
Total comprehensive income		215,977		977
Total comprehensive income attributable to:				
Owners of the parent		148,539		(7,972)
Non-controlling interests		67,438		8,949
Total comprehensive income	¥	215,977	¥	977

(3) Consolidated Statement of Changes in Equity

Third Quarter ended December 31, 2025

	Equity attributable to owners of the parent						
	Share capital	Capital surplus	Retained earnings	Treasury shares	Other components of equity		
					Remeasurements of financial assets measured at fair value through other comprehensive income	Remeasurements of defined benefit plans	
Millions of yen							
Balance as of April 1, 2025	¥ 90,059	¥ —	¥ 640,611	¥ (8,361)	¥ 1,186	¥ —	
Net income (loss)	—	—	87,363	—	—	—	
Other comprehensive income	—	—	—	—	25,587	325	
Total comprehensive income	—	—	87,363	—	25,587	325	
Issuance of new shares	120	120	—	—	—	—	
Purchase of treasury shares	—	—	—	(3)	—	—	
Disposal of treasury shares	—	(0)	—	0	—	—	
Dividends	—	—	(19,645)	—	—	—	
Changes resulting from loss of control of subsidiaries	—	—	1,789	—	(1,611)	(221)	
Changes in interest due to transactions with non-controlling interests	—	(3)	—	—	—	—	
Transfer from other components of equity to retained earnings	—	—	(12,335)	—	12,439	(104)	
Transfer to other comprehensive income associated with assets held for sale	—	—	—	—	—	—	
Total transactions with owners	120	117	(30,191)	(3)	10,828	(325)	
Balance as of December 31, 2025	¥ 90,179	¥ 117	¥ 697,783	¥ (8,364)	¥ 37,601	¥ —	

	Equity attributable to owners of the parent							Non-controlling interests	Total equity
	Other components of equity			Other comprehensive income associated with assets held for sale	Equity attributable to owners of the parent				
	Cash flow hedges	Exchange differences on conversion of foreign operations	Total						
Balance as of April 1, 2025	¥ 87	¥ 173,598	¥ 174,871	¥ 3,610	¥ 900,790	¥ 173,625	¥1,074,415		
Net income (loss)	—	—	—	—	87,363	56,783	144,146		
Other comprehensive income	57	53,789	79,758	(18,582)	61,176	10,655	71,831		
Total comprehensive income	57	53,789	79,758	(18,582)	148,539	67,438	215,977		
Issuance of new shares	—	—	—	—	240	—	240		
Purchase of treasury shares	—	—	—	—	(3)	—	(3)		
Disposal of treasury shares	—	—	—	—	0	—	0		
Dividends	—	—	—	—	(19,645)	(1,660)	(21,305)		
Changes resulting from loss of control of subsidiaries	—	—	(1,832)	43	—	(3,176)	(3,176)		
Changes in interest due to transactions with non-controlling interests	—	—	—	—	(3)	8	5		
Transfer from other components of equity to retained earnings	—	—	12,335	—	—	—	—		
Transfer to other comprehensive income associated with assets held for sale	—	(14,929)	(14,929)	14,929	—	—	—		
Total transactions with owners	—	(14,929)	(4,426)	14,972	(19,411)	(4,828)	(24,239)		
Balance as of December 31, 2025	¥ 144	¥ 212,458	¥ 250,203	¥ —	¥1,029,918	¥ 236,235	¥1,266,153		

Third Quarter ended December 31, 2024

	Equity attributable to owners of the parent						
	Share capital	Capital surplus	Retained earnings	Treasury shares	Other components of equity		
					Remeasurements of financial assets measured at fair value through other comprehensive income	Remeasurements of defined benefit plans	
Millions of yen							
Balance as of April 1, 2024	¥ 89,938	¥ 237	¥ 578,175	¥ (8,355)	¥ 83,448	¥ —	
Net income (loss)	—	—	28,581	—	—	—	
Other comprehensive income	—	—	—	—	(16,205)	138	
Total comprehensive income	—	—	28,581	—	(16,205)	138	
Issuance of new shares	120	120	—	—	—	—	
Purchase of treasury shares	—	—	—	(4)	—	—	
Disposal of treasury shares	—	(0)	—	0	—	—	
Dividends	—	—	(9,818)	—	—	—	
Changes resulting from loss of control of subsidiaries	—	—	—	—	—	—	
Changes in interest due to transactions with non-controlling interests	—	(306)	—	—	—	—	
Transfer from other components of equity to retained earnings	—	—	38,345	—	(38,207)	(138)	
Transfer to other comprehensive income associated with assets held for sale	—	—	—	—	(98)	—	
Total transactions with owners	120	(186)	28,527	(4)	(38,305)	(138)	
Balance as of December 31, 2024	¥ 90,059	¥ 51	¥ 635,283	¥ (8,359)	¥ 28,938	¥ —	

	Equity attributable to owners of the parent							Non-controlling interests	Total equity
	Other components of equity			Other comprehensive income associated with assets held for sale	Equity attributable to owners of the parent				
	Cash flow hedges	Exchange differences on conversion of foreign operations	Total						
Balance as of April 1, 2024	¥ 319	¥ 220,266	¥ 304,033	¥ 1,725	¥ 965,753	¥ 198,613	¥1,164,366		
Net income (loss)	—	—	—	—	28,581	12,113	40,694		
Other comprehensive income	(239)	(18,372)	(34,678)	(1,875)	(36,553)	(3,164)	(39,717)		
Total comprehensive income	(239)	(18,372)	(34,678)	(1,875)	(7,972)	8,949	977		
Issuance of new shares	—	—	—	—	240	—	240		
Purchase of treasury shares	—	—	—	—	(4)	—	(4)		
Disposal of treasury shares	—	—	—	—	0	—	0		
Dividends	—	—	—	—	(9,818)	(3,023)	(12,841)		
Changes resulting from loss of control of subsidiaries	—	—	—	—	—	28	28		
Changes in interest due to transactions with non-controlling interests	—	—	—	—	(306)	306	—		
Transfer from other components of equity to retained earnings	—	—	(38,345)	—	—	—	—		
Transfer to other comprehensive income associated with assets held for sale	—	(5,865)	(5,963)	5,963	—	—	—		
Total transactions with owners	—	(5,865)	(44,308)	5,963	(9,888)	(2,689)	(12,577)		
Balance as of December 31, 2024	¥ 80	¥ 196,029	¥ 225,047	¥ 5,813	¥ 947,894	¥ 204,873	¥1,152,767		

(4) Consolidated Statement of Cash Flows

Third Quarter ended December 31, 2025 and 2024

Millions of yen	Q3 FY2025	Q3 FY2024
Cash flows from operating activities:		
Income before taxes	¥ 144,399	¥ 40,071
Depreciation and amortization	90,425	99,431
Impairment losses	3,933	5,510
Gains on business transfers	(96,481)	(15,639)
Share of (profit) loss of investments accounted for using the equity method	43,212	(32,644)
Interest and dividend income	(9,267)	(13,086)
Interest expenses	24,260	22,479
Restructuring costs	5,871	14,824
(Gain) loss on sale of property, plant and equipment, and intangible assets	(1,148)	(11,469)
(Increase) decrease in trade receivables	23,919	31,719
(Increase) decrease in inventories	(33,202)	(8,165)
Increase (decrease) in trade payables	(4,975)	1,879
Increase (decrease) in unearned revenue	4,514	(18,248)
Increase (decrease) in provisions	10,167	5,883
Others, net	(59,572)	49,806
Subtotal	146,055	172,351
Interest and dividends received	12,627	17,724
Interest paid	(20,717)	(22,533)
Income taxes refund (paid)	(23,187)	(5,482)
Restructuring costs paid	(3,169)	(21,320)
Net cash provided by (used in) operating activities	111,609	140,740
Cash flows from investing activities:		
Net (increase) decrease in time deposits	(5,922)	(4,380)
Net (increase) decrease in securities	(13,849)	1,446
Purchase of property, plant and equipment, and intangible assets	(86,704)	(106,203)
Proceeds from sales of property, plant and equipment, and intangible assets	4,079	14,743
Proceeds from sales of subsidiaries	55,686	4,053
Payments for sales of subsidiaries	(20)	(3,000)
Purchase of other financial assets	(113,967)	(3,621)
Proceeds from sales and redemption of other financial assets	119,904	153,967
Others, net	957	(282)
Net cash provided by (used in) investing activities	(39,836)	56,723
Cash flows from financing activities:		
Net increase (decrease) in short-term borrowings	(29,862)	(34,443)
Net increase (decrease) in commercial paper	21,000	42,000
Proceeds from long-term borrowings	6,522	146
Repayments of long-term borrowings	(62,908)	(101,589)
Proceeds from issuance of bonds	—	99,161
Redemption of bonds	—	(120,000)
Repayments of finance lease liabilities	(13,410)	(14,257)
Cash dividends paid	(19,672)	(9,852)
Cash dividends paid to non-controlling interests	(1,662)	(3,025)
Others, net	(580)	177
Net cash provided by (used in) financing activities	(100,572)	(141,682)
Effect of exchange rate changes on cash and cash equivalents	11,505	(2,536)
Increase (decrease) in cash and cash equivalents	(17,294)	53,245
Cash and cash equivalents at the beginning of the year	209,838	217,449
Net increase (decrease) in cash and cash equivalents resulting from transfer to assets held for sale	22,224	(12,393)
Cash and cash equivalents at the end of the period	¥ 214,768	¥ 258,301

(5) Notes to Consolidated Financial Statements

Framework of Financial Report

The Group's quarterly consolidated financial statements are prepared in accordance with Article 5, Paragraph 2 of the Tokyo Stock Exchange, Inc.'s Standards for the Preparation of Quarterly Financial Statements, applying the omitted disclosures as set forth in Article 5, Paragraph 5 of the Standards for the Preparation of Quarterly Financial Statements.

Going Concern Assumption

Not applicable.

Segment Information

1. Reportable Segments

The reportable segments of the Group refer to business units for which separate financial information is available and that are reviewed regularly at the Board of Directors meeting in order to determine the allocation of management resources and evaluate the business performance of each business unit.

The Group divides its operations into business sectors identified by products and services, which manage manufacturing, sales, and research in an integrated manner. Each business sector is responsible for developing comprehensive domestic and overseas strategies with respect to its products and services, and operates its business activities.

Principally in accordance with the business sectors, the Group consists of the five reportable segments based on its products and services: "Agro & Life Solutions", "ICT & Mobility Solutions", "Advanced Medical Solutions", "Essential & Green Materials", and "Sumitomo Pharma".

Segment classification for certain consolidated subsidiaries was changed effective Q4 FY2024. The segment information for Q3 FY2024 has been reclassified to reflect this change.

The major products and services of each reportable segment are as follows:

Reportable Segment	Major Products and Services
Agro & Life Solutions	Crop protection chemicals, fertilizers, agricultural materials, household insecticides, products for control of infectious diseases, feed additives, etc.
ICT & Mobility Solutions	Optical products, semiconductor processing materials, compound semiconductor materials, touch screen sensor panels, high-purity aluminum and alumina, specialty chemicals, additives, engineering plastics, battery materials, etc.
Advanced Medical Solutions	Contract development and manufacturing organization business for advanced small-molecule drug, oligonucleotides, and regenerative medicine and cell therapy products, etc.
Essential & Green Materials	Synthetic resins, raw materials for synthetic fibers, various industrial chemicals, methyl methacrylate products, synthetic resin processed products, industrial alumina, synthetic rubber, etc.
Sumitomo Pharma	Small molecule pharmaceuticals

2. Reportable Segment Information

The accounting methods for each reportable segment are, in principle, identical to those used in the consolidated financial statements. The segment profit or loss is core operating income, which is calculated from operating income after excluding effects from non-recurring factors.

Inter-segment sales revenue is based on market prices.

Third Quarter Fiscal Year 2025

Millions of yen	Agro & Life Solutions	ICT & Mobility Solutions	Advanced Medical Solutions	Essential & Green Materials	Sumitomo Pharma	Total	Others (Note 3)	Adjustments (Note 4)	Consolidated
Sales revenue:									
Sales revenues from external customers	¥ 346,864	¥ 431,785	¥ 35,628	¥ 510,986	¥ 346,417	¥ 1,671,680	¥ 34,647	¥ —	¥ 1,706,327
Inter-segment sales revenues	771	1,661	8,459	3,578	1,329	15,798	36,860	(52,658)	—
Total sales revenue	347,635	433,446	44,087	514,564	347,746	1,687,478	71,507	(52,658)	1,706,327
Segment profit (loss) : core operating income (loss)	¥ 28,099	¥ 46,528	¥ 273	¥ 19,775	¥ 111,244	¥ 205,919	¥ 4,983	¥ (24,068)	¥ 186,834

Note 1: ¥19,775 million for segment profit (core operating income) in "Essential & Green Materials" includes ¥55,807 million for gain related to business transfer.

Note 2: ¥111,244 million for segment profit (core operating income) in "Sumitomo Pharma" includes ¥49,927 million for gain related to business transfer.

Note 3: "Others" represents businesses such as supplying electrical power and steam, and providing transport and warehousing, which are not included in reportable segments. Due to the sale of the radiopharmaceutical business and other businesses in FY2024, sales revenue decreased compared to Q3 FY2024.

Note 4: ¥(24,068) million for segment profit (loss) in "Adjustments" includes inter-segment elimination of ¥796 million and corporate expenses of ¥(24,864) million unallocated to each reportable segment. Corporate expenses are mainly research and development expenses for company-wide research, which are not treated as attributable to specific reportable segments.

Third Quarter Fiscal Year 2024

Millions of yen	Agro & Life Solutions	ICT & Mobility Solutions	Advanced Medical Solutions	Essential & Green Materials	Sumitomo Pharma	Total	Others (Note 1)	Adjustments (Note 2)	Consolidated
Sales revenue:									
Sales revenues from external customers	¥ 363,076	¥ 461,216	¥ 40,728	¥ 672,915	¥ 292,815	¥ 1,830,750	¥ 74,083	¥ —	¥ 1,904,833
Inter-segment sales revenues	1,214	2,607	6,854	4,059	66	14,800	49,594	(64,394)	—
Total sales revenue	364,290	463,823	47,582	676,974	292,881	1,845,550	123,677	(64,394)	1,904,833
Segment profit (loss) : core operating income (loss)	¥ 19,517	¥ 59,720	¥ 1,203	¥ (44,340)	¥ 24,391	¥ 60,491	¥ 23,752	¥ (24,178)	¥ 60,065

Note 1: "Others" represented businesses such as radiopharmaceuticals, supplying electrical power and steam, providing services for the design, engineering, and construction management of chemical plants, and providing transport and warehousing, which were not included in reportable segments.

Note 2: ¥(24,178) million for segment profit (loss) in "Adjustments" included inter-segment elimination of ¥392 million and corporate expenses of ¥(24,570) million unallocated to each reportable segment. Corporate expenses were mainly research and development expenses for company-wide research, which were not treated as attributable to specific reportable segments.

Adjustments to income (loss) before taxes from core operating income (loss) were as follows:

Millions of yen	Q3 FY2025		Q3 FY2024	
Core operating income	¥	186,834	¥	60,065
Restructuring costs		(5,871)		(14,824)
Impairment losses		(3,933)		(5,510)
Gains on sales of property, plant and equipment, and intangible assets		1,148		11,469
Share of profit of investments accounted for using the equity method (non-recurring factors)		—		85,987
Gains on fair value measurement of the residual interest		—		9,449
Others, net		2,238		(1,202)
Operating income		180,416		145,434
Finance income		12,395		34,757
Finance expenses		(48,412)		(140,120)
Income before taxes	¥	144,399	¥	40,071

Note: Breakdown of share of profit (loss) of investments accounted for using the equity method included in operating income was as follows:

Millions of yen	Q3 FY2025		Q3 FY2024	
Share of profit (loss) of investments accounted for using the equity method	¥	(43,212)	¥	32,644
Of which resulting from recurring factors		(43,212)		(53,343)
Of which resulting from non-recurring factors		—		85,987

Key Figures of Consolidated Financial Results for 3rd Quarter FY2025

February 3, 2026
Sumitomo Chemical Co., Ltd.
(Billions of yen)

1. Financial Summary (IFRS)

	Q3 FY2025	Q3 FY2024	Variance	FY2025 (Revised Forecast announced Feb.)	FY2024
Sales revenue	1,706.3	1,904.8	(198.5)	2,300.0	2,606.3
Core operating income	186.8	60.1	126.8	200.0	140.5
Operating income	180.4	145.4	35.0	165.0	193.0
Net income attributable to owners of the parent	87.4	28.6	58.8	55.0	38.6
Basic earnings per share	¥ 53.38	¥ 17.47	¥ 35.91	¥ 33.61	¥23.59
Return on equity	9.0%	3.0%	6.0%	5.8%	4.1%
Exchange rate (yen/\$)	148.71	152.64	—	149.03 (Jan.-Mar. 150.00)	152.62
Naphtha price (yen/kl)	65,000	76,400	—	64,600 (Jan.-Mar. 63,500)	75,600

*Core operating income is a gain and loss concept that reflects recurring earning capacity by deducting gains and losses incurred by non-recurring factors from operating income, which includes the share of profits or losses from investments accounted for using the equity method.

2. Sales Revenue / Core Operating Income by Business Segment (IFRS)

(Billions of yen)

		Q3 FY2025	Q3 FY2024	Variance	FY2025 (Revised Forecast announced Feb.)	FY2024
Agro & Life Solutions	Sales revenue	346.9	363.1	(16.2)	530.0	540.2
	Core operating income	28.1	19.5	8.6	55.0	55.0
ICT & Mobility Solutions	Sales revenue	431.8	461.2	(29.4)	560.0	607.0
	Core operating income	46.5	59.7	(13.2)	55.0	70.6
Advanced Medical Solutions	Sales revenue	35.6	40.7	(5.1)	60.0	62.1
	Core operating income	0.3	1.2	(0.9)	4.0	4.0
Essential & Green Materials	Sales revenue	511.0	672.9	(161.9)	680.0	899.0
	Core operating income	19.8	(44.3)	64.1	13.0	(58.5)
Sumitomo Pharma	Sales revenue	346.4	292.8	53.6	420.0	398.0
	Core operating income	111.2	24.4	86.9	100.0	35.3
Others	Sales revenue	34.6	74.1	(39.4)	50.0	99.9
	Core operating income	5.0	23.8	(18.8)	5.0	66.9
Adjustments	Sales revenue	—	—	—	—	—
	Core operating income	(24.1)	(24.2)	0.1	(32.0)	(32.7)
Total	Sales revenue	1,706.3	1,904.8	(198.5)	2,300.0	2,606.3
	Core operating income	186.8	60.1	126.8	200.0	140.5

*The segment information for Q3 FY2024 has been reclassified to reflect the change in segment classification of certain consolidated subsidiaries in Q4 FY2024.

3. Summary of Consolidated Statement of Income (IFRS)

(Billions of yen)

	Q3 FY2025	Q3 FY2024	Variance	Variance Ratio
Sales revenue	1,706.3	1,904.8	(198.5)	(10.4)%
Core operating income	186.8	60.1	126.8	211.1%
of which equity-method investments	(43.2)	(53.3)	10.1	—
Total non-recurring items (breakdown below)	(6.4)	85.4	(91.8)	—
Restructuring costs	(5.9)	(14.8)	9.0	—
Impairment losses	(3.9)	(5.5)	1.6	—
Gains on sales of property, plant and equipment, and intangible assets	1.1	11.5	(10.3)	—
Share of profit of investments accounted for using the equity method (non-recurring factors)	—	86.0	(86.0)	—
Gains on fair value measurement of the residual interest	—	9.4	(9.4)	—
Others	2.2	(1.2)	3.4	—
Operating income	180.4	145.4	35.0	24.1%
Finance income/expenses (breakdown below)	(36.0)	(105.4)	69.3	—
Gain (loss) on foreign currency transactions including gain (loss) on derivatives	(7.7)	15.0	(22.8)	—
Loss on valuation of investment securities	(13.6)	—	(13.6)	—
Loss on debt waiver for a loan	—	(109.8)	109.8	—
Others	(14.7)	(10.6)	(4.1)	—
Income before taxes	144.4	40.1	104.3	260.4%
Income tax expenses	(0.3)	0.6	(0.9)	—
Net income	144.1	40.7	103.5	254.2%
Net (income) loss attributable to non-controlling interests	(56.8)	(12.1)	(44.7)	—
Net income attributable to owners of the parent	87.4	28.6	58.8	205.7%
ROE	9.0%	3.0%		
Exchange rate (yen/\$)	148.71	152.64		
Naphtha price (yen/kl)	65,000	76,400		
Overseas sales revenue ratio	71.2%	69.8%		

4. Summary of Consolidated Statement of Financial Position (IFRS)

(Billions of yen)

	31-Dec-25	31-Mar-25	Variance		31-Dec-25	31-Mar-25	Variance
Current assets	1,600.8	1,583.1	17.7	Liabilities	2,244.3	2,365.4	(121.1)
Cash and cash equivalents	214.8	209.8	4.9	Trade and other payables	473.6	488.1	(14.5)
Trade and other receivables	604.6	593.8	10.8	Interest-bearing liabilities	1,221.5	1,286.1	(64.6)
Inventories	661.4	625.2	36.2	Others	549.2	591.1	(41.9)
Others	120.0	154.2	(34.2)	Equity	1,266.2	1,074.4	191.7
Non-current assets	1,909.6	1,856.7	53.0	Shareholders' equity	779.7	722.3	57.4
Property, plant and equipment	773.4	759.3	14.1	Other components of equity	250.2	178.5	71.7
Goodwill and intangible assets	498.4	497.1	1.2	Non-controlling interests	236.2	173.6	62.6
Others	637.9	600.3	37.6				
Total	3,510.4	3,439.8	70.6	Total	3,510.4	3,439.8	70.6
				Ratio of equity attributable to owners of the parent to total assets	29.3%	26.2%	3.2%
				D/E ratio (times)	0.96	1.20	(0.23)

5. Summary of Consolidated Statement of Cash Flows (IFRS)

	Q3 FY2025	Q3 FY2024	Variance	(Billions of yen) FY2024
Cash flows from operating activities	111.6	140.7	(29.1)	233.0
Cash flows from investing activities	(39.8)	56.7	(96.6)	85.2
Free cash flows	71.8	197.5	(125.7)	318.3
Cash flows from financing activities	(100.6)	(141.7)	41.1	(300.8)
Others	11.5	(2.5)	14.0	(6.8)
Increase (decrease) in cash and cash equivalents	(17.3)	53.2	(70.5)	10.7
Cash and cash equivalents at the end of the period	214.8	258.3	(43.5)	209.8